bioAffinity technologies has announced record revenue and unit sales for its lung cancer diagnostic cyPath lung in 2025. The company's recent performance is reportedly driving a surge in interest, with its stock making notable movements in the market. Various financial outlets are covering the news and providing analysis of the company's stock.